1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Cervarix is manufactured and marketed by GSK, and consists of recombinant VLPs of the L1 capsid proteins from HPV strains 16 and 18, produced using a Baculovirus expression system. VLPs are combined with GSK’s proprietary AS04 adjuvant, adsorbed on aluminum hydroxide. Cervarix is administered as a three-dose schedule with the second and third doses at one and six months following the first dose, respectively.

Scope

- Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cervarix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cervarix for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HPV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cervarix performance
- Obtain sales forecast for Cervarix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia)

Table Of Contents

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Symptoms 13
4 Vaccination Recommendations and Coverage Rates 15
4.1 Vaccination Recommendations Overview 15
5 Competitive Assessment 17
5.1 Overview 17
5.2 Strategic Competitor Assessment 17
6 Cervarix 20
6.1 Overview 20
6.2 Efficacy 22
6.3 Safety 23
6.4 SWOT Analysis 24
6.5 Forecast 24
7 Appendix 26
7.1 Bibliography 26
7.2 Abbreviations 32
7.3 Methodology 34
7.4 Forecasting Methodology 34
7.4.1 Vaccine Coverage 35
7.4.2 Vaccine Approval versus Routine Schedule Inclusion 35
7.4.3 General Pricing Assumptions 36
7.4.4 Individual Drug Assumptions 37
7.5 Physicians and Specialists Included in this Study 38
7.6 About the Author(s) 41
7.6.1 Author(s) 41
7.6.2 Therapy Area Director 41
7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43

1.1 List of Tables

Table 1: Histological Progression Towards Cervical Cancer 12
Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms 14
Table 3: HPV Vaccine Recommendation Agencies by Country 16
Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014 16
Table 5: Marketed Vaccines for HPV, 2014 19
Table 6: Product Profile - Cervarix 21
Table 7: Phase III Efficacy Trials - Cervarix 22
Table 8: Safety Profile - Cervarix 23
Table 9: Cervarix SWOT Analysis, 2014 24
Table 10: Global Sales Forecasts ($m) for Cervarix, 2012-2022 25
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017-2021 World Sexually-Transmitted Disease (STD) Diagnostics Market: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis--Supplier Shares, Sales Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation

2017-2021 World Sexually-Transmitted Disease (STD) Diagnostics Market: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis--Supplier Shares, Sales Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation

  • $ 9600
  • Industry report
  • January 2017
  • by Venture Planning Group

About this Report This report presents a detailed analysis of the STD market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.  Current scientific views on epidemiology and etiology are ...

2017-2021 Sexually-Transmitted Diseases (STD) Diagnostic Testing Market

2017-2021 Sexually-Transmitted Diseases (STD) Diagnostic Testing Market

  • $ 6200
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200. This new 350-page report from VPGMarketResearch.com contains 90 tables and provides analysis of the global s ...

2017-2021 World Sexually-Transmitted Diseases (STD) Market: Global Opportunities and Growth Strategies for Suppliers

2017-2021 World Sexually-Transmitted Diseases (STD) Market: Global Opportunities and Growth Strategies for Suppliers

  • $ 6200
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200. This new 350-page report from VPGMarketResearch.com contains 90 tables and provides analysis of the global s ...


Download Unlimited Documents from Trusted Public Sources

Tuberculosis Statistics

  • February 2017
    200 pages
  • Infectious Dise...  

    Tuberculosis  

  • United States  

    North America  

    Europe  

View report >

Blood Supply Industry in Namibia and Africa

  • February 2017
    209 pages
  • Health Care Pro...  

    Blood Supply  

    HIV AIDS  

  • Namibia  

    Africa  

    World  

View report >

Sexually Transmitted Disease Statistics in India

  • February 2017
    10 pages
  • Sexually Transm...  

    Infectious Dise...  

  • India  

View report >

Related Market Segments :

Sexually Transmitted Disease

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.